Statin therapy has been shown cost-effective for lowering cholesterol in young adults, according to a study published in the Journal of the American College of Cardiology.
Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved heart failure-related symptoms and physical limitations in patients with heart failure with preserved ejection fraction.
Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to a recent clinical trial.
Donald Lloyd-Jones, MD, ScM, chair of Preventive Medicine and the Eileen M. Foell Professor of Heart Research, and current president of the American Heart Association, recently testified before Congress in support of legislation that would improve cardiovascular health in the U.S.
A machine learning model can identify patients at risk of a rare cardiomyopathy, according to a recent study.
Epigenetic aging could serve as a promising biomarker for measuring long-term cardiovascular health and disease risk, according to a recent Northwestern Medicine study.
Genomic autopsy of young individuals who experienced sudden death revealed many had known genetic variants that are associated with cardiomyopathy.
Inefficient cardiac repair after heart attacks is partially driven by a maladapted response to a low oxygen environment by immune cells, according to a study published in the Journal of Experimental Medicine.
Thirty-five years since it was started, the Coronary Artery Risk Development in Young Adults study, or CARDIA, has become a premier source for the determinants, mechanism and outcomes of cardiovascular disease and manifestations of aging.
Risk factors such as hypertension, diabetes and smoking conferred greater risk of heart failure in young and middle aged individuals when compared with older individuals, according to a recent study.